Stock Comparison

ABCL vs LLY

Abcellera Biologics Inc vs Eli Lilly and Co

The Verdict

ABCL takes this one.

Winner

ABCL

Abcellera Biologics Inc

7.2

out of 10

Solid Pick

LLY

Eli Lilly and Co

0.5

out of 10

Distressed

Head-to-Head

$1.2B

Market Cap

$965.0B

-8.0

P/E Ratio

52.6

-194.9%

Profit Margin

N/A

-14.8%

Return on Equity

N/A

0.1

Debt-to-Equity

N/A

Aggressive

Overall Risk

Moderate

7.2

DVR Score

0.5

The Deep Dive

ABCL7.2/10

AbCellera continues to hold significant 10x potential, driven by its cutting-edge AI-powered antibody discovery platform and a strategic pivot towards internal drug development. The substantial Q4 2025 revenue beat and the impending Phase 1/Phase 2 data for ABCL635 are strong positive catalysts, de-risking its pipeline and demonstrating execution. While the company still grapples with negative pro...

Full ABCL Analysis

LLY0.5/10

Eli Lilly remains a pharmaceutical powerhouse with exceptional market leadership, especially driven by its GLP-1 agonist franchise (Mounjaro/Zepbound). The company possesses a robust R&D pipeline and substantial competitive advantages through intellectual property and scale. While LLY offers strong long-term growth and stability, its current market capitalization exceeding $1 trillion makes achiev...

Full LLY Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.